Targeted Liposomes Modulating WASp Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia primarily focus on symptom management rather than modifying WASp expression and function, and hematopoietic malignancies associated with overexpressed WASp proteins pose a challenge due to increased cell migration, invasion, and metastasis, leading to poor prognosis.
Innovation Solution
Development of liposomes that target hematopoietic cells overexpressing WASp, incorporating antibodies specific to activated lymphocytes and oligonucleotides or peptides to decrease WASp gene expression or enhance its degradation, thereby reducing malignancy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments focus on symptom management rather than modifying WASp expression, then treatment simplicity is maintained, but treatment effectiveness is limited
Solution Approach 1:
The treatment approach is segmented into two distinct components: a targeting component (antibody against LFA-1) that directs the therapy to malignant cells, and a therapeutic component (oligonucleotide or degrading agent) that modifies WASp expression. This segmentation allows the complex mechanism to be delivered through a manageable liposome structure.
Solution Approach 2:
Liposomes serve as intermediary carriers that bridge the gap between the therapeutic agent and the target cells. The liposome encapsulates the oligonucleotide or degrading agent and delivers it specifically to malignant hematopoietic cells through antibody-mediated targeting, enabling effective WASp modulation without direct administration of complex molecules.
2Ease of operation
If WASp expression is overexpressed in malignant cells, then cell migration and invasion increase, but this also provides a specific target for therapy
Solution Approach 1:
The treatment exploits the local quality difference in WASp expression levels between malignant and normal cells. By targeting specifically to cells with overexpressed WASp and its associated markers (LFA-1), the therapy achieves localized action where it is most needed, reducing harm to normal tissues while effectively treating the malignant cells.
Solution Approach 2:
The overexpression of WASp and associated markers in malignant cells, which normally contributes to their harmful invasive behavior, is converted into a benefit by serving as a specific target for the antibody-directed liposome therapy. The same molecular features that enable malignancy progression now facilitate precise therapeutic delivery.
3Reliability
If oligonucleotides are used to decrease WASp gene expression, then malignancy is reduced, but delivery to specific cells becomes challenging
Solution Approach 1:
The oligonucleotide is nested within the liposome structure, which itself is targeted by the antibody. This nested arrangement protects the oligonucleotide from degradation in circulation and ensures its delivery to the intracellular environment where it can effectively reduce WASp gene expression.
Solution Approach 2:
The liposome serves multiple functions simultaneously: it acts as a protective carrier for the oligonucleotide, provides targeting specificity through the attached antibody, and facilitates cellular uptake. This multi-functionality simplifies the overall delivery system compared to using separate components for each function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted liposomes effectively decrease WASp expression or enhance its degradation in malignant cells, potentially reducing metastasis and improving treatment outcomes for hematopoietic malignancies and genetic disorders like WAS and XLT.
Implementation Method 1
a liposome that targets a hematopoietic cell, hereinafter a 'hematopoietic cell targeting liposome' (HTL), comprising an antibody directed towards a molecule preferentially or uniquely expressed on activated lymphocytes
Implementation Method 2
The HTL may be attracted to and fuse with a malignant hematopoietic cell, thereby introducing into the cell an oligonucleotide capable of decreasing WASp gene expression
Implementation Method 3
The HTL may be attracted to and fuse with a malignant hematopoietic cell, thereby introducing into the cell an oligonucleotide capable of decreasing WASp gene expression
Implementation Method 4
The HTL may comprise an agent (hereinafter a WASp degrading agent) that increases WASp degradation
Data Source
AI summary
Embodiments of the invention relate to liposomes comprising: a lipid bilayer having an internal cavity; a therapeutic agent within the internal cavity configured to modify expression or degradation of WASp in a cell; and a targeting moiety external to the lipid bilayer configured to target an extracellular domain of a cell. Embodiments of the invention relate to methods of treatment of disease comprising administering the liposomes. Novel pharmaceutical compositions are also disclosed.